Replies to post #118700 on Biotech Values

[sodrock]

I believe what he means is that if TEVA were to launch Laquidimod; they may introduce the "weighting" of a sales reps responsibility for detailing to say 85% Laq and 15% Copax. However if the commercial success isn't as successful compared to the other Oral MS medications you may see an adjustment in weighting to protect Copaxone share in the US. So instead of a rep being compensated more heavily toward to Laquinimod you may see an even distribution of weight say more like 60/40 or 50/50; representatives would be compensated accordingly.

Detailing would mean continuing to promote Copaxone and spend funds on Copaxone in office for lunches, speaker programs etc to protect that revenue stream.